February 25, 2007 – Last week, the Centient Biotech 200™ dropped by less than a point to close at 4053. In terms of breadth, the numbers were split, much as might be expected for a week that did not produce much change. The IPO market will kick back into gear next week after a two-week hiatus, with OcoGenex and Rosetta Genomics on the docket. The post-IPO trading is one of the bright spots in biotech, and Optimer Pharma, a 2007 IPO, is now up 42% in the two weeks since it made its debut. Cortex Pharma was up 62% on hopes its ADHD drug can overcome FDA fears of toxicity; Icagen rose 39%; NeoPharm was 31% higher; Corcept gained 25%; and Bruker BioSciences rose 19% on strong earnings. More details...
